Cash/Burn From SEC Filing For Period: 

Q3 '19

RYTM

Rhythm Pharmaceuticals

Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity.

Cash

$162.4M

Burn Rate

$36.0M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Setmelanotide

Leptin Receptor Deficiency Obesity

NDA Filing

2Q 2020

Setmelanotide

POMC deficiency obesity

NDA Filing

2Q 2020

Setmelanotide

Bardet-Biedl Syndrome

Phase 3

1Q 2020

Setmelanotide

Alstrom Syndrome

Phase 3

1Q 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon